This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Arthrocare Device Use Draws More Scrutiny

"This is another milestone in Arthrocare's continued growth, as we continue to bring in-house those capabilities critical to our future," Arthrocare CEO Michael Baker boasted when announcing the transaction this January. "This acquisition will significantly enhance our capabilities to support all of our businesses with a reimbursement service offering" down the road.

By purchasing DiscoCare -- and then expanding its reach -- some feel that Arthrocare has invited serious trouble instead.

"Because of its acquisition of DiscoCare and its prior disclosures regarding marketing 'our DiscoCare model,' Arthrocare has placed itself in the middle of what appears to be a major investigation by the FBI into potential billing fraud," says one Arthrocare investor who has sold the company's stock short in anticipation of a fall. "Investors should now ask themselves this: Is Arthrocare an unintentional facilitator to what may be a multi-hundred-million-dollar insurance fraud, or is it a full accomplice?"

Arthrocare declined to comment for this story. In the past, however, the company has repeatedly proclaimed its innocence and that of DiscoCare.

It has stirred up suspicions, nonetheless.

Even before the FBI started seeking their help, car insurers were scrutinizing the so-called "DiscoCare model." Indeed, one of them had subpoenaed Arthrocare's leading executives -- including its CEO and its spine chief -- in an effort to prove that the DiscoCare model is actually a massive insurance scam.

Those subpoenas came shortly after Arthrocare purchased DiscoCare and officially took control of the company. Since then, Arthrocare has gone on to announce a looming restatement due to improper transactions with DiscoCare and some other firms that seem to resemble it.

4 of 5

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
SYM TRADE IT LAST %CHG
ARTC $48.60 0.08%
ALL $67.31 0.00%
AIG $58.15 0.00%
PGR $26.83 0.00%
AAPL $125.01 0.00%

Markets

DOW 17,841.98 -86.22 -0.48%
S&P 500 2,080.15 -9.31 -0.45%
NASDAQ 4,919.6440 -19.6830 -0.40%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs